-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 2nd, the world's leading biopharmaceutical company Sanofi held a signing ceremony for the insulin expansion project of its production base in Beijing on the 1st and the 25th anniversary of its establishment in Beijing.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
Yin Yong, Member of the Standing Committee of the Beijing Municipal Committee and Deputy Mayor, and French Ambassador to China Mr.
Luo Liang attended and witnessed the signing ceremony.
Luo Liang attended and witnessed the signing ceremony.
Yin Yong said that Sanofi has invested and built a factory in Beijing for 25 years, witnessing the process of China's reform and opening up, and growing together with China.
In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
The French ambassador to China, Mr.
Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Dr.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
With the continuous improvement of Chinese people's living standards and changes in dietary structure, the number of diabetic patients has risen by nearly 120 million, ranking first in the world.
Zhang Ping, head of Sanofi's China Industrial Affairs Department, said that as one of the first multinational pharmaceutical companies to enter the Chinese market, Sanofi's three production bases in China have always focused on meeting the health service needs of Chinese patients.
.
.
In December 1995, Sanofi's Beijing production base officially settled in Beijing Economic and Technological Development Zone.
Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
Medical Network, June 2nd, the world's leading biopharmaceutical company Sanofi held a signing ceremony for the insulin expansion project of its production base in Beijing on the 1st and the 25th anniversary of its establishment in Beijing.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
Yin Yong, Member of the Standing Committee of the Beijing Municipal Committee and Deputy Mayor, and French Ambassador to China Mr.
Luo Liang attended and witnessed the signing ceremony.
Luo Liang attended and witnessed the signing ceremony.
Yin Yong said that Sanofi has invested and built a factory in Beijing for 25 years, witnessing the process of China's reform and opening up, and growing together with China.
In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
The French ambassador to China, Mr.
Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Dr.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
With the continuous improvement of Chinese people's living standards and changes in dietary structure, the number of diabetic patients has risen by nearly 120 million, ranking first in the world.
Zhang Ping, head of Sanofi's China Industrial Affairs Department, said that as one of the first multinational pharmaceutical companies to enter the Chinese market, Sanofi's three production bases in China have always focused on meeting the health service needs of Chinese patients.
.
.
In December 1995, Sanofi's Beijing production base officially settled in Beijing Economic and Technological Development Zone.
Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
Medical Network, June 2nd, the world's leading biopharmaceutical company Sanofi held a signing ceremony for the insulin expansion project of its production base in Beijing on the 1st and the 25th anniversary of its establishment in Beijing.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
This move not only shows the French company's firm confidence in the Chinese market, but also fulfills its promise to provide health services to Chinese residents.
Yin Yong, Member of the Standing Committee of the Beijing Municipal Committee and Deputy Mayor, and French Ambassador to China Mr.
Luo Liang attended and witnessed the signing ceremony.
Luo Liang attended and witnessed the signing ceremony.
Yin Yong said that Sanofi has invested and built a factory in Beijing for 25 years, witnessing the process of China's reform and opening up, and growing together with China.
In the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
Enterprise business enterprise health health healthIn the future, it is hoped that leading companies in the global medical field, including Sanofi, can seize the opportunity of China's reform and opening up and introduce more advanced medical and health products and services into China.
The French ambassador to China, Mr.
Luo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Medicine Medicine MedicineLuo Liang, is pleased with the long-term cooperative partnership between China and France in the field of medicine and health.
He said that Sanofi's history in China is the best example of the long-term partnership between the two countries.
Dr.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
He Enting, President of Sanofi Greater China, said that the expansion of insulin production is one of Sanofi's measures to improve its overall layout in China.
It not only shows Sanofi's firm confidence in the Chinese market, but also fulfills its promise to protect the health of the Chinese people.
With the continuous improvement of Chinese people's living standards and changes in dietary structure, the number of diabetic patients has risen by nearly 120 million, ranking first in the world.
Diet, diet, diet Zhang Ping, head of Sanofi's China Industrial Affairs Department, said that as one of the first multinational pharmaceutical companies to enter the Chinese market, Sanofi's three production bases in China have always focused on meeting the health service needs of Chinese patients.
.
.
In December 1995, Sanofi's Beijing production base officially settled in Beijing Economic and Technological Development Zone.
Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
Standard Standard Standard Following the global unified high- standard quality management system and precise process management, through continuous investment, expansion and upgrading, the base already has the world's advanced insulin production lines such as insulin glargine injection filling lines.
At the same time, the production base drives "green development" with "green production", and was named a "green factory" by the Ministry of Industry and Information Technology of China in 2020.
(Finish)
